
The Glaring Reason Why Warren Buffett Isn't Buying His Favorite ETF Right Now
Past clues point to the Vanguard S&P 500 ETF being Buffett's favorite exchange-traded fund.
The legendary investor isn't buying his favorite ETF because of a dangerously high valuation.
Buying the Vanguard S&P 500 ETF even at a high valuation could pay off over the long term, but only if you buy and hold.
10 stocks we like better than Vanguard S&P 500 ETF ›
Warren Buffett loves investing in stocks. However, he doesn't encourage all investors to follow in his footsteps. Instead, the Oracle of Omaha believes that the best approach for most people is to invest in funds rather than individual stocks.
His premise is that it takes a lot of research to understand businesses well enough to put your money at risk investing in them. Exchange-traded funds (ETFs) own lots of stocks, so extensive research isn't required. And they can be bought and sold just like stocks.
While there are thousands of ETFs on the market, Buffett especially likes one. But there's a glaring reason why even Buffett isn't buying his favorite ETF right now.
Buffett's favorite ETF
What is Buffett's favorite ETF? He has provided three big clues in the past.
Clue No. 1 came in Buffett's 2013 letter to Berkshire Hathaway (NYSE: BRK.A)(NYSE: BRK.B) shareholders. He wrote: "The goal of the non-professional should not be to pick winners -- neither he nor his 'helpers' can do that -- but should rather be to own a cross-section of businesses that in aggregate are bound to do well. A low-cost S&P 500 index fund will achieve this goal."
Buffett's second clue was in the same shareholder letter. And it was even more direct. He noted that his will specifies that 90% of the cash his family inherits when he dies be invested "in a very low-cost S&P 500 index fund." He then added, "I suggest Vanguard's."
Now for the third clue. Buffett has owned only two ETFs in recent years in Berkshire's portfolio. One was the SPDR S&P 500 ETF Trust (NYSEMKT: SPY). The other was the Vanguard S&P 500 ETF (NYSEMKT: VOO), which has a slightly lower annual expense ratio than the SPDR ETF.
Guess which one of these two S&P 500 (SNPINDEX: ^GSPC) index funds had more of Berkshire's cash invested in it? Pat yourself on the back if your answer was the Vanguard ETF. I think these clues clearly point to the Vanguard S&P 500 ETF as Buffett's favorite ETF.
Why he isn't buying it
However, Berkshire completely exited its position in the Vanguard S&P 500 ETF in the fourth quarter of 2024. (It sold all of its shares of the SPDR S&P 500 ETF Trust during the quarter as well.) Furthermore, the legendary investor has not bought a single share of his favorite ETF since.
I don't think Buffett has changed his mind about the wisdom of investing in S&P 500 index funds. I don't believe he no longer views the Vanguard S&P 500 ETF as a good long-term pick for investors, either. So why isn't Buffett buying his favorite ETF? I think the glaring reason is...valuation.
One metric that highlights the concerning valuation of the Vanguard S&P 500 ETF and the overall stock market is named after Buffett himself. The Buffett indicator measures the total market capitalization of all U.S. stocks as a percentage of U.S. GDP.
Buffett stated in an article published by Fortune magazine in 2001 that when this indicator approaches 200%, investors are "playing with fire." Today, the Buffett indicator stands at nearly 209%. Granted, this metric uses the Wilshire 5000 index, which includes all U.S. stocks. However, the S&P 500 makes up around 80% of the total market capitalization of U.S. stocks.
Should you buy this ETF even though Buffett isn't?
Buffett's warning about "playing with fire" rings in my ears. So does his advice in the 2013 Berkshire Hathaway shareholder letter to "invest in stocks as you would in a farm." I probably wouldn't buy a farm when land prices were at all-time highs, especially if I suspected they would be cheaper in the not-too-distant future.
That said, I don't think investors would make a huge mistake by buying the Vanguard S&P 500 ETF right now, even though Buffett isn't -- if they hold the ETF for the long term. I'd be surprised if the S&P 500 (and ETFs that track the index) aren't valued more highly 20 years from now than they are today.
Buffett pointed out a risk to keep in mind, though. He wrote in the 2013 letter, "The main danger is that the timid or beginning investor will enter the market at a time of extreme exuberance and then become disillusioned when paper losses occur." If you think you'll succumb to the temptation to sell if the Vanguard S&P 500 ETF declines sharply, don't buy it.
However, Buffett also provided an "antidote" to this potential problem. He suggested accumulating shares over time and never selling on bad news or major pullbacks. If you follow these rules, Buffett argued, you're "virtually certain to get satisfactory results."
Should you invest $1,000 in Vanguard S&P 500 ETF right now?
Before you buy stock in Vanguard S&P 500 ETF, consider this:
The Motley Fool Stock Advisor analyst team just identified what they believe are the 10 best stocks for investors to buy now… and Vanguard S&P 500 ETF wasn't one of them. The 10 stocks that made the cut could produce monster returns in the coming years.
Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you'd have $687,149!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you'd have $1,060,406!*
Now, it's worth noting Stock Advisor's total average return is 1,069% — a market-crushing outperformance compared to 180% for the S&P 500. Don't miss out on the latest top 10 list, available when you join Stock Advisor.
See the 10 stocks »
*Stock Advisor returns as of July 15, 2025
Hashtags

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles


National Post
12 minutes ago
- National Post
Simpro Group Hires Industry Veteran to Help Drive Strategic Field Services Transformation in North America
Proven trades operator, Amy Carnrick, brings hands-on expertise to strengthen Simpro's commitment to field service excellence. Article content BROOMFIELD, Colo. — Simpro Group, a global leader in field service management solutions, today announced the appointment of Amy Carnrick as Senior Advisor, Field Service Transformation. This strategic hire reinforces the evolving market landscape surrounding private equity-backed FSM consolidation and Simpro's mission to empower trade and field service businesses with innovative software solutions that drive growth and operational success. Article content 'Amy embodies everything we value at Simpro – she's a hands-on operator who understands the real challenges facing field service businesses because she's lived them,' said Gary Specter, CEO of Simpro Group. Article content Since acquiring Foster Plumbing in 2018, Carnrick has demonstrated extraordinary vision and expertise in the trades industry. Drawing on her entrepreneurial mindset and deep operations expertise, she spearheaded the strategic adoption of Simpro technology at Foster Plumbing, doubling business revenue, expanding into new markets, and earning national accolades, including the 2023 Small Business Person of the Year (U.S. Small Business Administration, Colorado) and the 2024 Top 50 Colorado Companies to Watch. Article content 'Amy embodies everything we value at Simpro – she's a hands-on operator who understands the real challenges facing field service businesses because she's lived them,' said Gary Specter, CEO of Simpro Group. 'Her proven ability to scale businesses and deliver impactful results aligns perfectly with our mission to help trade and field service organizations thrive.' Article content In her new role, Carnrick will play a pivotal part in amplifying Simpro's presence in the North American market. Focusing on the digital transformations happening across the trades industry, she will work closely with Simpro's go-to-market, product, and partner teams to deliver best-in-class, actionable solutions that address customer needs, including expanding the company's growing partner ecosystem. Additionally, she will drive initiatives to shape product innovation and strategy, further cementing Simpro's position as a trusted field service leader. Article content 'I'm passionate about helping trade businesses achieve their full potential,' Carnrick shared. 'Having experienced first-hand how transformative the right field service management solution can be, I'm looking forward to now helping Simpro tell powerful, peer-grounded stories that show other operators what's possible when they have the right tools and strategy in place.' Article content About Simpro Group Article content Simpro Group provides best-in-class SaaS field service management solutions to trade and field service businesses worldwide. The group comprises four industry-leading companies, Simpro, BigChange, AroFlo and ClockShark with offices across North America, Australia, New Zealand and the UK. Simpro, BigChange and AroFlo provide comprehensive field service management software for growth-minded trade and field service businesses, while ClockShark specializes in time-tracking and scheduling software solutions. Together, these companies seek to drive businesses forward with solutions that empower teams to work smarter, provide foundations for business scaling, and offer data-driven insights to fuel decision-making. Ready to transform your business? Explore our products at Article content , Article content , Article content Article content and Article content Article content . Article content Article content Article content Article content Contacts Article content

National Post
12 minutes ago
- National Post
Pluristyx Completes Investment Round to Expand Product Portfolio and Commercial Operations
Article content SEATTLE — Pluristyx, a leading provider of induced pluripotent stem cell (iPSC) technologies and proprietary gene editing solutions, today announced the successful close of its most recent round of funding led by BioLife Solutions, the global leader in cryopreservation technologies and systems that support cell and gene therapy (CGT) manufacturing, and BroadOak Capital Partners, a specialist investor in the life science tools and services industry. Article content The newly raised capital will enable Pluristyx to expand inventory with new clinical grade cell lines incorporating Pluristyx's proprietary FailSafe® and iACT™ engineering and hypoimmune genetic edits in its best-in-class, polyclonal, synthetic RNA reprogramed iPSCs. These proprietary cells are specifically designed to support making next-generation genetically engineered, stem cell-derived therapies and support uniquely safe, effective, and scalable living medicines. The funding will also support Pluristyx's recently launched PluriForm ™ kit, which provides researchers with streamlined tools for generating organoids and other complex test systems. Article content 'We are incredibly excited for the successful close of this round and gratified to have industry leaders and peers validate our vision with their investment,' said Benjamin Fryer, PhD, CEO of Pluristyx. 'The support from our Seattle area neighbor, BioLife Solutions, and continued support from our colleagues at BroadOak Partners will allow us to manufacture, commercialize, and distribute our innovative solutions and help our customers solve critical industry challenges.' Article content Roderick de Greef, BioLife's Chairman and CEO, remarked, 'We have known and worked with the founding team at Pluristyx for many years, and have a great deal of respect for their scientific expertise in cell therapy. Their recent development of an iPSC-based biological assay for organoid manufacturing dovetails with our interest in exploring biological assays more broadly as a product portfolio adjacency.' Article content 'We are excited to continue our support of Dr. Fryer and the entire Pluristyx team,' said Daniel Friedman, Principal at BroadOak Capital Partners. 'Pluristyx is differentiated by its suite of proprietary technologies that directly address some of the most critical scientific challenges of the iPSC field.' Article content iPSCs are unique tools and building blocks for medicines. In addition to applications for innovative new toxicology, safety, and efficacy assays to replace animal models, Pluristyx's products are the ideal universal raw material to produce living medicines to cure currently untreatable diseases. This strategic investment will enable Pluristyx to be the industry leader offering the highest quality stem cells available anywhere. Article content About BioLife Solutions Article content BioLife Solutions is a leading developer and supplier of bioproduction products and services for the cell and gene therapy (CGT) and broader biopharma markets. Our expertise facilitates the commercialization of new therapies by supplying solutions that maintain the health and function of biologic materials during collection, development, storage, and distribution. For more information, please visit or follow BioLife on LinkedIn and X. Article content About BroadOak Capital Partners Article content BroadOak Capital Partners is a boutique financial institution that provides direct investment and investment banking services to companies in the life science tools, diagnostics, and biopharma services sectors. BroadOak has led or participated in investments in over 70 companies across the life sciences industry. For more information, visit Article content Pluristyx is dedicated to enabling the development of next-generation cell-based tools and therapies. PluriKit™, PluriForm™ Organoids, and PluriBank™ stem cells incorporating safety and tolerance features like FailSafe®, iACT™, and hypoimmune engineering streamline developers' path to the clinic and approval. Pluristyx's iPSC lines, backed by an FDA registered drug master file, with platform genetic engineering are available 'off-the-shelf' along with comprehensive support services to accelerate the creation of novel diagnostics, screening and safety testing, and curative treatments. For more information, visit Article content Article content Article content Article content


Globe and Mail
12 minutes ago
- Globe and Mail
Cover Whale Announces $40 Million in Growth Equity Financing from Morgan Stanley Expansion Capital to Fund Growth Initiatives
Cover Whale Insurance Solutions, Inc., a leading insurtech specializing in connected insurance for commercial auto, announced $40 million in new equity financing from Morgan Stanley Expansion Capital. The financing will enable Cover Whale to accelerate investments in its technology platform, analytics, and expand its product offerings to drive increased growth and profitability. Founded in 2020, Cover Whale's proprietary technology platform and algorithmic underwriting enables agents to bind trucking insurance policies online in minutes. By leveraging real-time telematics and other data sources, Cover Whale continuously underwrites policies throughout their term, achieving industry-leading loss ratios in the traditionally challenging commercial trucking market segment. Commenting on the financing, Dan Abrahamsen, Founder and CEO of Cover Whale, said: 'After years of rapid growth, 2024 marked a pivotal year for Cover Whale as we focused on re-building our foundation. We invested in our technology platform, built a high-performing service organization, and refined our pricing, underwriting and loss control programs. Morgan Stanley Expansion Capital's transition from lender to equity partner is a gratifying affirmation of the tremendous progress made over the past few years, and their renewed backing gives us the resources to fully capitalize on the significant growth opportunities ahead.' Year to date, Cover Whale has $133 million of gross written premiums during the first half of 2025, on track for a full-year target of $277 million. Morgan Stanley Expansion Capital first invested in Cover Whale in May 2024 with a structured debt instrument. 'Today's growth equity investment reflects our conviction in Cover Whale's business strategy, execution and leadership team,' said Nick Nocito, Executive Director of Morgan Stanley Expansion Capital. 'Over the last 18 months, the team has built a high-quality, scalable platform that we believe will generate significant growth in the coming years.' About Cover Whale Cover Whale is a leading insurtech on a mission to make commercial auto insurance faster, easier, and smarter—for agents, policyholders, and the broader insurance ecosystem. Grounded in technology, automation, and the strategic use of AI and real-time data, Cover Whale offers the industry's fastest quote and bind platform, while delivering industry leading loss ratios. The company's proprietary driver safety program combines continuous underwriting, real-time risk monitoring, telematics, and AI-powered driver coaching to reduce losses, reward safe driving, and improve road safety for both covered drivers and the motoring public. Operating as a managing general agent (MGA), Cover Whale has partnered with nearly 5,000 agents to write more than $1.3 billion in gross premium, since its inception in 2020. As it has grown, the organization has earned recognition across the industry, including being named a top insurtech to watch by PropertyCasualty360 and one of Forbes' Best Startup Employers. To learn more, visit and stay current via LinkedIn, Facebook, and their blog. About Morgan Stanley Expansion Capital Morgan Stanley Expansion Capital is the growth-focused private investment platform within Morgan Stanley Investment Management. MSEC targets late-stage growth equity and credit investments within technology, consumer, healthcare, and other high-growth sectors. For nearly four decades, Morgan Stanley Expansion Capital has successfully pursued growth investment opportunities and has completed investments in over 220 companies, leveraging the global brand and network of Morgan Stanley. About Morgan Stanley Investment Management Morgan Stanley Investment Management, together with its investment advisory affiliates, has over 1,400 investment professionals around the world and $1.7 trillion in assets under management or supervision as of June 30, 2025. Morgan Stanley Investment Management strives to provide outstanding long-term investment performance, client service, and a comprehensive suite of investment management solutions to a diverse client base, which includes governments, institutions, corporations, and individuals worldwide. For further information about Morgan Stanley Investment Management, please visit About Morgan Stanley